MA51433A - Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase - Google Patents
Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinaseInfo
- Publication number
- MA51433A MA51433A MA051433A MA51433A MA51433A MA 51433 A MA51433 A MA 51433A MA 051433 A MA051433 A MA 051433A MA 51433 A MA51433 A MA 51433A MA 51433 A MA51433 A MA 51433A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitor
- piperidine derivative
- aminomethyl piperidine
- aminomethyl
- derivative
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- DBMHTLOVZSDLFD-UHFFFAOYSA-N piperidin-1-ylmethanamine Chemical class NCN1CCCCC1 DBMHTLOVZSDLFD-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170183062A KR102577242B1 (ko) | 2017-12-28 | 2017-12-28 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51433A true MA51433A (fr) | 2021-04-07 |
Family
ID=67067897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051433A MA51433A (fr) | 2017-12-28 | 2018-12-28 | Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase |
Country Status (22)
Country | Link |
---|---|
US (1) | US11407754B2 (fr) |
EP (1) | EP3733674B1 (fr) |
JP (1) | JP7024091B2 (fr) |
KR (1) | KR102577242B1 (fr) |
CN (1) | CN111527088B (fr) |
AU (1) | AU2018394996B2 (fr) |
BR (1) | BR112020013237A2 (fr) |
CA (1) | CA3085160C (fr) |
CL (1) | CL2020001749A1 (fr) |
CO (1) | CO2020007156A2 (fr) |
DO (1) | DOP2020000111A (fr) |
EC (1) | ECSP20035588A (fr) |
ES (1) | ES2924225T3 (fr) |
MA (1) | MA51433A (fr) |
MX (1) | MX2020006798A (fr) |
MY (1) | MY196572A (fr) |
PE (1) | PE20210549A1 (fr) |
RU (1) | RU2756505C1 (fr) |
SA (1) | SA520412334B1 (fr) |
SG (1) | SG11202004916YA (fr) |
TN (1) | TN2020000081A1 (fr) |
WO (1) | WO2019132561A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10392368B2 (en) | 2017-08-01 | 2019-08-27 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
RU2758370C1 (ru) | 2017-12-28 | 2021-10-28 | Даевунг Фармасьютикал Ко., Лтд. | Производные оксифторпиперидина в качестве ингибитора киназы |
WO2020154350A1 (fr) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine,1,2,4-triazolo[4,3-a]pyridine et imidazo[1,5-a]pyrazine utilisées en tant qu'inhibiteurs de jak |
KR102228668B1 (ko) * | 2019-10-08 | 2021-03-17 | (주)부흥산업사 | 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법 |
CN112824381B (zh) * | 2019-11-21 | 2024-04-26 | 广东东阳光药业股份有限公司 | 一种哌啶胺的制备方法 |
US11697648B2 (en) | 2019-11-26 | 2023-07-11 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as JAK inhibitors |
CN113214265B (zh) * | 2020-01-21 | 2023-07-07 | 江苏先声药业有限公司 | 嘧啶并五元环类化合物 |
WO2021147953A1 (fr) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | Dérivé cyclique pyrimidino à cinq chaînons et application correspondante |
CN115023428A (zh) * | 2020-01-21 | 2022-09-06 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
TW202214643A (zh) * | 2020-09-22 | 2022-04-16 | 大陸商江蘇先聲藥業有限公司 | 嘧啶并吡咯類化合物 |
CN114315838B (zh) * | 2020-09-30 | 2024-09-03 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
WO2023165562A1 (fr) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | Composé hétérocyclique contenant de l'azote et son utilisation |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
EP3311818A3 (fr) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibiteurs de tyrosine-kinase de bruton pour le traitement de tumeurs solides |
WO2010129053A2 (fr) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Inhibiteurs d'egfr et procédés de traitement de troubles |
HUE032515T2 (en) | 2010-06-23 | 2017-09-28 | Hanmi Science Co Ltd | New condensed pyrimidine derivatives for inhibiting tyrosine kinase activity |
CA2847540C (fr) * | 2011-09-22 | 2016-05-17 | Pfizer Inc. | Derives de pyrrolopyrimidine et de purine |
MX361992B (es) * | 2012-08-06 | 2018-12-19 | Acea Biosciences Inc | Compuestos de pirrolopirimidina novedosos como inhibidores de proteínas quinasas. |
WO2014073987A1 (fr) | 2012-11-08 | 2014-05-15 | Compac Technologies Limited | Support d'articles pour un appareil de classement |
WO2014113429A2 (fr) | 2013-01-16 | 2014-07-24 | Signal Pharmaceuticals, Llc | Composés de type pyrrolopyrimidine substituée, compositions en contenant et méthodes de traitement faisant appel à eux |
KR101879422B1 (ko) | 2013-09-18 | 2018-07-17 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물 |
KR101930603B1 (ko) | 2013-12-05 | 2018-12-18 | 화이자 인코포레이티드 | 피롤로[2,3-d]피리미디닐, 피롤로[2,3-b]피라지닐 및 피롤로[2,3-d]피리디닐 아크릴아미드 |
CN105732637B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
AU2016369584A1 (en) | 2015-12-16 | 2018-07-19 | Southern Research Institute | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof |
US10961247B2 (en) * | 2016-06-30 | 2021-03-30 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
CN106432294B (zh) | 2016-09-19 | 2018-01-30 | 淮北师范大学 | 发光配合物及其制备方法 |
KR102032418B1 (ko) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
RU2758370C1 (ru) | 2017-12-28 | 2021-10-28 | Даевунг Фармасьютикал Ко., Лтд. | Производные оксифторпиперидина в качестве ингибитора киназы |
KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
-
2017
- 2017-12-28 KR KR1020170183062A patent/KR102577242B1/ko active IP Right Grant
-
2018
- 2018-12-28 EP EP18897615.3A patent/EP3733674B1/fr active Active
- 2018-12-28 MY MYPI2020002466A patent/MY196572A/en unknown
- 2018-12-28 PE PE2020000794A patent/PE20210549A1/es unknown
- 2018-12-28 CN CN201880083535.6A patent/CN111527088B/zh active Active
- 2018-12-28 WO PCT/KR2018/016813 patent/WO2019132561A1/fr unknown
- 2018-12-28 RU RU2020124575A patent/RU2756505C1/ru active
- 2018-12-28 JP JP2020534937A patent/JP7024091B2/ja active Active
- 2018-12-28 MX MX2020006798A patent/MX2020006798A/es unknown
- 2018-12-28 SG SG11202004916YA patent/SG11202004916YA/en unknown
- 2018-12-28 ES ES18897615T patent/ES2924225T3/es active Active
- 2018-12-28 CA CA3085160A patent/CA3085160C/fr active Active
- 2018-12-28 MA MA051433A patent/MA51433A/fr unknown
- 2018-12-28 US US16/770,213 patent/US11407754B2/en active Active
- 2018-12-28 AU AU2018394996A patent/AU2018394996B2/en active Active
- 2018-12-28 TN TNP/2020/000081A patent/TN2020000081A1/en unknown
- 2018-12-28 BR BR112020013237-3A patent/BR112020013237A2/pt unknown
-
2020
- 2020-06-10 DO DO2020000111A patent/DOP2020000111A/es unknown
- 2020-06-11 CO CONC2020/0007156A patent/CO2020007156A2/es unknown
- 2020-06-25 SA SA520412334A patent/SA520412334B1/ar unknown
- 2020-06-26 CL CL2020001749A patent/CL2020001749A1/es unknown
- 2020-06-29 EC ECSENADI202035588A patent/ECSP20035588A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP7024091B2 (ja) | 2022-02-22 |
ECSP20035588A (es) | 2020-07-31 |
SA520412334B1 (ar) | 2022-11-03 |
ES2924225T3 (es) | 2022-10-05 |
KR20190080541A (ko) | 2019-07-08 |
WO2019132561A8 (fr) | 2020-06-11 |
NZ765152A (en) | 2024-02-23 |
AU2018394996A2 (en) | 2020-07-16 |
CO2020007156A2 (es) | 2020-06-19 |
WO2019132561A1 (fr) | 2019-07-04 |
KR102577242B1 (ko) | 2023-09-11 |
AU2018394996B2 (en) | 2021-08-05 |
EP3733674A1 (fr) | 2020-11-04 |
US20210188854A1 (en) | 2021-06-24 |
EP3733674B1 (fr) | 2022-06-29 |
MY196572A (en) | 2023-04-19 |
CN111527088B (zh) | 2022-12-30 |
US11407754B2 (en) | 2022-08-09 |
DOP2020000111A (es) | 2020-09-30 |
SG11202004916YA (en) | 2020-06-29 |
EP3733674A4 (fr) | 2021-06-09 |
CA3085160A1 (fr) | 2019-07-04 |
TN2020000081A1 (en) | 2022-01-06 |
CA3085160C (fr) | 2021-12-07 |
RU2756505C1 (ru) | 2021-10-01 |
PE20210549A1 (es) | 2021-03-17 |
CL2020001749A1 (es) | 2020-11-06 |
CN111527088A (zh) | 2020-08-11 |
BR112020013237A2 (pt) | 2020-12-01 |
MX2020006798A (es) | 2020-09-03 |
AU2018394996A1 (en) | 2020-06-25 |
JP2021507923A (ja) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51433A (fr) | Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase | |
MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
MA55194A (fr) | Composés hétérocycliques en tant qu'immunomodulateurs | |
MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
BR112017027339A2 (pt) | derivados de piperidina 1,4-substituída | |
MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
MA47573A (fr) | Inhibiteurs de dihydrobenzofurane glycosidase substitués | |
MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 | |
MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
MA47736A (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 | |
FR3034987B1 (fr) | Composition a base de trans-resveratrol ou d'un derive de trans-resveratrol | |
DK3405287T3 (da) | Slidbeskyttelseselement til en fragmenteringsmaskine | |
MA51284A (fr) | Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho |